Chemical chaperone therapy: Luciferase assay for screening of β-galactosidase mutations

Molecular Genetics and Metabolism

Volumn 101, Issue 4, 2010, Pages 364-369

  Li, Linjing ^a,b   Higaki, Katsumi ^a   Ninomiya, Haruaki ^b   Luan, Zhuo ^b   Iida, Masami ^c   Ogawa, Seiichiro ^d   Suzuki, Yoshiyuki ^e   Ohno, Kousaku ^b   Nanba, Eiji ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c SEIKAGAKU CORPORATION   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

galactosidase; Chemical chaperone therapy; GM1 gangliosidosis; Luciferase; Lysosomal storage disease; Neurodegeneration

Indexed keywords

BETA GALACTOSIDASE; CHAPERONE; LUCIFERASE; N OCTYL 4 EPI BETA VALIENAMINE; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVITY; ENZYME ASSAY; GENE MUTATION; MISSENSE MUTATION; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL;

AMMONIUM CHLORIDE; ANIMALS; BETA-GALACTOSIDASE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; DINOFLAGELLIDA; DNA, COMPLEMENTARY; GENETIC HETEROGENEITY; HEXOSAMINES; HUMANS; LUCIFERASES; MOLECULAR CHAPERONES; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; RECOMBINANT PROTEINS; TRANSFECTION;

DINOPHYCEAE;

EID: 78649331806     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.08.012     Document Type: Article

References (28)

1. M1-gangliosidosis and Morquio B disease. The Online Metabolic and Molecular Bases of Inherited Disease 2008, McGraw-Hill, New York, Chapter 151. D. Valle, A.L. Beaudet, B. Vogelstein, K.W. Kinzler, S.F. Antoanarakis (Eds.).
2. M1 gangliosidosis: review of clinical, molecular and therapeutic aspects. Mol. Genet. Metab. 2008, 94:391-396.
3. M1 gangliosidosis and Morquio B disease: expression analysis of missense mutations affecting the catalytic site of acid beta-galactosidase. Hum. Hutat. 2009, 30:1214-1221.
4. M1-gangliosidosis. J. Inherit. Metab. Dis. 2005, 28:797-798.
5. M1 gangliosidosis mice by neonatal intravenous gene transfer. Gene Ther. 2005, 10:1487-1493.
6. M1 gangliosidosis. J. Neurochem. 2004, 89:645-653.
7. Brady R.O., Schiffmann R. Enzyme-replacement therapy for metabolic storage disorder. Lancet Neurol. 2004, 3:752-756.
8. Fan J.Q., Ishii S., Asano N., Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by en enzyme inhibitor. Nat. Med. 1999, 5:112-115.
9. M1-gangliosidosis. Proc. Natl Acad. Sci. USA 2003, 100:15912-15917.
10. Suzuki Y., Ichinomiya S., Kurosawa M., Ohkubi M., Watanabe H., Iwasaki H., Matsuda J., Noguchi Y., Takimoto K., Itoh M., Tabe M., Iida M., Kubo T., Ogawa S., Nanba E., Higaki K., Ohno K., Brady R.O. Chemical chaperone therapy. clinical effect in murine GM1-gangliosidosis 2007, 62:671-675.
11. Iwasaki H., Watanabe H., Iida M., Ogawa S., Tabe M., Higaki K., Nanba E., Suzuki Y. Fibroblast screening for chaperone therapy in β-galactosidosis. Brain Dev. 2006, 28:482-486.
12. Rowe L., Dikici E., Daunert S. Engineering bioluminescent proteins: expanding their analytical potential. Anal. Chem. 2009, 81:8662-8668.
13. Lembert N., Odahl L.A. Regulatory effects on ATP and luciferin on firefly luciferase activity. Biochem. J. 1995, 305:929-933.
14. Morkova S.V., Golz S., Frank L.A., Kalthof B. Cloning and expression of cDNA for a luciferase from the marine copepod Metridia longa. J. Biol. Chem. 2004, 279:3212-3217.
15. Suzuki C., Nakajima Y., Akimoto H., Wu C., Ohmiya Y. A new additional reporter enzyme, dinoflagellate luciferase, for monitoring of gene expression in mammalian cells. Gene 2005, 344:61-66.
16. Wurdinger T., Badr C., Pike L., de Kleine R., Weisslender R., Breakefield X.O., Tannous B.A. A secreted luciferase for ex vivo monitoring of in vivo process. Nat. Meth. 2008, 5:171-173.
17. Ogawa S., Matsunaga Y.K., Suzuki Y. Chemical modification of the β-glucocerebrosidase inhibitor N-octyl-β-valienamne: synthesis and biological evaluation of 4-epimeric and 4-O-(β-d-galactopyranosyl) derivatives. Bioorg. Med. Chem. 2002, 10:1967-1972.
18. Takiyama N., Itoh K., Oshima A., Sakuraba H., Suzuki Y. Characterization of an anti-g-galactosidase antibody recognizing a precursor but not a mature enzyme in solution. Biochem. Biophys. Res. Commun. 1993, 193:526-531.
19. Sawkar A.R., Cheng W.C., Beutler E., Wong C.H., Balch W.E., Kelly J.W. Chemical chaperones increase the cellular activity of N370S β-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl Acad. Sci. USA 2002, 99:15428-15433.
20. Oshima A., Yoshida K., Itoh K., Kase R., Sakuraba H., Suzuki Y. Intracellular processing and maturation of mutant gene products in hereditary β-galactosidase deficiency (β-galactosidosis). Hum. Genet. 1994, 93:109-114.
21. Mu T.W., Ong D.S., Wang Y.J., Balch W.E., Yates J.R., Segatori L., Kelly J.W. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 2008, 134:769-781.
22. Suzuki Y. β-galactosidase deficiency: an approach to chaperone therapy. J. Inherit. Metab. Dis. 2006, 29:471-476.
23. Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol. Med. 2009, 1:268-279.
24. Lin H., Sugimoto Y., Ohsaki Y., Ninomiy H., Oka A., Taniguchi M., Ida H., Eto Y., Ogawa S., Matsuzaki Y., Sawa M., Inoue T., Higaki K., Nanba E., Ohno K., Suzuki Y. N-octyl-β-valienamine up-regulates activity of F213I mutant β-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease. Biochim. Biophys. Acta 2004, 1689:219-228.
25. Steet R.A., Chung S., Wustman B., Powe A., Do H., Kornfeld S.A. The iminosugar isofagomine increases the activity of N370S mutant acid β-glucosidase in Gaucher fibroblasts by several mechanisms. Proc. Natl Acad. Sci. USA 2006, 103:13813-13818.
26. M2 gangliosidosis cells. FEBS J. 2007, 274:4951-4961.
27. Luan Z., Higaki K., Aguilar-Moncayo M., Ninomiya H., Ohno K., Garcia-Moreno M.I., Ortiz Mellet M.I.C., García Fernández J.M., Suzuki Y. Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nomyl)deoxynojirimycin. Chembiochem 2009, 10:2780-2792.
28. Fan F., Wood K.V. Bioluminescent assays for high-throughput screening. Assay Drug Dev. Technol. 2007, 5:127-136.